Elegen, a leader in cell-free DNA manufacturing, has officially launched ENFINIA™ IVT Ready DNA. This innovative product is designed for immediate use in in vitro transcription (IVT), reducing the time needed for developing mRNA-based therapeutics by weeks.

The ENFINIA IVT Ready DNA provides high-fidelity, long linear DNA with encoded poly(A) tails, and it does so up to three times faster than traditional methods. Plasmid-derived templates, which are typically used for IVT, often face challenges such as failures or delays, particularly with complex sequences. These plasmids are circular and must be propagated in bacteria, requiring additional processing and quality checks before they can be utilized in IVT. Elegen’s ENFINIA IVT Ready DNA addresses these issues by offering ready-to-use templates in as little as 10 business days, thereby streamlining mRNA therapeutic development while minimizing variability and eliminating contamination risks.

“Researchers can now evaluate and develop novel therapeutic modalities faster than ever,” said Matt Hill, founder and CEO of Elegen. “Producing accurate linear DNA with long poly(A) tails without bacteria eliminates the drawbacks of plasmids, bringing greater speed and reliability to mRNA synthesis.”

Using plasmids can also restrict design options, necessitate cumbersome workflows, and lead to inconsistent quality—factors that can impede the progress of AI-driven mRNA development, where both speed and complexity are essential. Elegen’s cell-free approach overcomes these limitations by providing diverse linear, NGS-verified DNA template designs of up to 5.5 kb, complete with encoded poly(A) tails (70–130 nt).

Elegen has successfully completed early access testing of hundreds of template designs with over 20 biotechnology, biopharma, and government partners. The company has shared its latest findings on the quality and performance of ENFINIA IVT Ready DNA templates in a webinar that is now available on demand.